Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| See historical AUPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 22 | Fell Below 20 DMA | Bearish | 0.00% |
| Mar 22 | Fell Below 50 DMA | Bearish | 0.00% |
| Mar 22 | Earnings Movers | Other | 0.00% |
| Mar 21 | Bearish Engulfing | Bearish | -4.15% |
| Mar 21 | 20 DMA Support | Bullish | -4.15% |
| Mar 21 | 50 DMA Support | Bullish | -4.15% |
| Mar 21 | Calm After Storm | Range Contraction | -4.15% |
| Mar 21 | Earnings Movers | Other | -4.15% |
| Mar 20 | Crossed Above 20 DMA | Bullish | -5.27% |
| Mar 20 | Crossed Above 50 DMA | Bullish | -5.27% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-21
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Diseases Immunosuppressants Peptides Lupus Lupus Nephritis Treatment Of Lupus
Medicine Biopharmaceutical Life Sciences Drugs Autoimmune Diseases Immunosuppressants Peptides Lupus Lupus Nephritis Treatment Of Lupus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AUPH news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 7.85 |
| 52 Week Low | 5.01 |
| Average Volume | 1,016,681 |
| 200-Day Moving Average | 5.9564 |
| 50-Day Moving Average | 6.6206 |
| 20-Day Moving Average | 6.565 |
| 10-Day Moving Average | 6.414 |
| Average True Range | 0.3012 |
| ADX | 14.89 |
| +DI | 27.2014 |
| -DI | 15.629 |
| Chandelier Exit (Long, 3 ATRs ) | 6.4764 |
| Chandelier Exit (Short, 3 ATRs ) | 6.9036 |
| Upper Bollinger Band | 7.1435 |
| Lower Bollinger Band | 5.9865 |
| Percent B (%b) | 0.42 |
| BandWidth | 17.623762 |
| MACD Line | -0.0075 |
| MACD Signal Line | -0.0327 |
| MACD Histogram | 0.0252 |
| Fundamentals | Value |
|---|---|
| Market Cap | 540.15 Million |
| Num Shares | 83.5 Million |
| EPS | -1.30 |
| Price-to-Earnings (P/E) Ratio | -4.98 |
| Price-to-Sales | 1112.47 |
| Price-to-Book | 2.62 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.03 | ||||
| Resistance 3 (R3) | 7.09 | 6.96 | 6.93 | ||
| Resistance 2 (R2) | 6.96 | 6.82 | 6.93 | 6.90 | |
| Resistance 1 (R1) | 6.72 | 6.73 | 6.66 | 6.66 | 6.87 |
| Pivot Point | 6.59 | 6.59 | 6.56 | 6.56 | 6.59 |
| Support 1 (S1) | 6.35 | 6.45 | 6.29 | 6.29 | 6.07 |
| Support 2 (S2) | 6.22 | 6.36 | 6.19 | 6.04 | |
| Support 3 (S3) | 5.98 | 6.22 | 6.01 | ||
| Support 4 (S4) | 5.92 |
